BiVictriX Therapeutics gets US Patent providing broad protection for BVX001
ALDERLEY PARK, LONDON: BiVictriX Therapeutics plc (AIM: BVX), an emerging biotechnology company applying a differentiated approach to develop next-generation cancer therapies with substantially improved cancer cell selectivity and anti-cancer activity, announces that the United States Patent and Trademark Office (USPTO)…